Merck
HomeProductsPharma & Biopharma ManufacturingBioprocessing Cell CultureViral Vector Upstream Platforms

Viral Vector Upstream Platforms

The VirusExpress™ Lentiviral Production Platform features a suspension adapted cell line, chemically defined medium, and production process with proven performance

Figure 1.The VirusExpress® Production Platform features a suspension adapted cell line, chemically defined medium, and production process with proven performance.

The VirusExpress® Production Platform offers a transfection-based solution to lentivirus (LV) or adeno-associated virus (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and production process with proven performance at up to 50 L scale.

With a platform that can dramatically reduce the time in process development and scale-up, whether performed in your facilities or leveraging our gene therapy CDMO capabilities, you can draw on our experience to speed your gene therapy to patients.

Request Information

Related Product Resources

Interview: Industrializing Viral Vector Manufacture
App Note: Optimized Cell Culture Medium for Scalable Viral Vector Production
Data Sheet: VirusExpress® Lentiviral Production Platform
Brochure: VirusExpress® 293 AAV Production Platform

Key Advantages Include

  • GMP banked and fully characterized cell bank manufactured in accordance with 21 CFR 210, 211, 600, 610
  • Proven performance for cell growth, plasmid transfection, and production in large-scale bioreactors at clinically and commercially relevant scale
  • Licenses available for research or clinical/commercial use
  • Reduction of up to 40% in process development and scale-up time

The VirusExpress® Production Platforms Include

VirusExpress® 293T Lentiviral Production Cells or VirusExpress® 293 AAV Production Cells

  • Cells banked and characterized in conformance with FDA cGMP regulations (21 CFR 201, 211, 600, 610)
  • Suspension-adapted cells
  • Cells optimized for transient transfection processes

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically-defined, animal component-free, cGMP manufactured cell culture medium

Proven Process

  • Upstream production and downstream purification processes developed at clinically relevant scale

Virusexpress® Lentivirus Production Platform Performance

For performance data on VirusExpress® 293 AAV Production Platform, click here.

Cell Growth and Viability Cell viability (dashed lined) and cell growth data (solid lines)

Cell Growth and Viability

Cell viability (dashed lined) and cell growth data (solid lines)

Titer values of three unique bioreactor runs Each run exceeded a target functional titer of 10000000 TU/mL and demonstrated successful scale-up to 40 L

Titer values of three unique bioreactor runs

Each run exceeded a target functional titer of 1 x 107 TU/mL and demonstrated successful scale-up to 40 L


VirusExpress® Production Platform Specifications

Related Product Categories

Bioprocessing Single-Use Bioreactors
Mobius® single-use bioreactors are scalable, configurable, and reliable, able to perform fed-batch and perfusion bioprocessing at any scale from benchtop to full-scale production.
Clarification Depth Filters & Pretreatment Solutions
To prepare your cell culture harvest for downstream chromatography and purification, our Millistak+® and Clarisolve® depth filters and flocculation polymers offer upstream process solutions for both primary and secondary clarification. Millistak+® HC and HC Pro can be used as polishing filters at a certain point in the downstream purification process.
Downstream Process & Formulation Chemicals
Our broad portfolio of downstream chemicals simplifies raw material specification with optimized quality attributes for all your applications – while providing industry-leading support and documentation to help navigate regulatory challenges, manage risks, and improve processes.

Related Applications

Gene Therapy Manufacturing
Growing use of gene therapies is driving rapid innovation in an evolving global market. Manufacturers bringing new gene therapies to life face complex challenges, requiring an experienced partner capable of integrating vector manufacturing, testing, safety, process development, and regulatory compliance.
Viral Vector Characterization and Biosafety Testing
As gene therapy products continue to show promise, biosafety testing and characterization remain a critical part of the development process. These vital steps help mitigate safety concerns and provide a better understanding of products and processes well in advance of patient administration.

Related Services

Viral Vector CTDMO Services
Our viral and gene therapy manufacturing site in Carlsbad, California has produced over 1,000 batches of virus, meeting rigorous timelines for more than 20 years with a complete range of services, a state-of-the-art cGMP facility, and deep regulatory understanding.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?